US FDA approves first non-gene edited allogeneic CAR T-cell candidate for trials
Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad.
Archives for August 15, 2018
LenioBio and Fraunhofer Institute to develop protein expression platform
LenioBio and Fraunhofer Institute IME have entered a licensing agreement, allowing LenioBio to commercialize technology into a protein expression platform.
US FDA grants Breakthrough Therapy Designation for food allergy drug Xolair
Genentech’s Xolair was granted a Breakthrough Therapy Designation by the US FDA.